GLP-1 receptor agonists and heart failure in diabetes.

[en] The prevalence of heart failure (HF) is increasing in patients with type 2 diabetes (T2D), and glucose-lowering agents have distinctive effects on the risk of developing HF that requires hospitalization. Such an increased risk has been consistently reported with thiazolidinediones (glitazones) and perhaps also with the dipeptidyl peptidase (DPP)-4 inhibitor saxagliptin (at least in SAVOR - TIMI 53), whereas a markedly decreased risk was highlighted with the sodium - glucose cotransporter type 2 (SGLT2) inhibitor empagliflozin in EMPA-REG OUTCOME. Yet, the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on myocardial function remain controversial. Whereas some promising observations have been reported in various animal models, the effects of GLP-1RAs on myocardial function in humans are more heterogeneous, while the positive effect on left ventricular ejection fraction (LVEF), if any, appears to be inconsistent and rather modest in most patients with HF. However, no increased risk of hospitalization for HF has been reported with GLP-1RAs in meta-analyses of phase-II/III trials (exenatide, albiglutide, dulaglutide, liraglutide), demonstrating the safety of this pharmacological class, and such findings have been confirmed by three large prospective cardiovascular outcome trials (ELIXA with lixisenatide, LEADER with liraglutide and SUSTAIN-6 with semaglutide). In particular, LEADER reported a trend towards a reduction in HF hospitalization (-13%, P = 0.14), together with a significant reduction in cardiovascular and all-cause mortality in patients with T2D at risk of cardiovascular disease. These results are reassuring in the face of the somewhat negative results of the FIGHT trial, which evaluated the effects of liraglutide in patients with advanced HF and low LVEF, such that further studies and caution are now required when using this agent to treat such patients in clinical practice.

Disciplines :

Cardiovascular & respiratory systems
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège > Département des sciences cliniques > Département des sciences cliniques

Language :

English

Title :

GLP-1 receptor agonists and heart failure in diabetes.

Publication date :

2017

Journal title :

Diabetes and Metabolism

ISSN :

1262-3636

eISSN :

1878-1780

Publisher :

Elsevier Masson, Paris, France

Volume :

43 Suppl 1

Pages :

2S13-2S19

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 11 May 2017

Statistics

Number of views

1337 (3 by ULiège)

Number of downloads

2261 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

[1] Thomas, M.C., Type 2 diabetes and heart failure: challenges and solutions. Curr Cardiol Rev 12 (2016), 249–255.
[2] Scheen, A.J., Charbonnel, B., Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal. Diabetes Metab 40 (2014), 176–185.
[3] Retnakaran, R., Zinman, B., Type 1 diabetes, hyperglycaemia, and the heart. Lancet 371 (2008), 1790–1799.
[4] Standl, E., Schnell, O., McGuire, D.K., Heart failure considerations of antihyperglycemic medications for type 2 diabetes. Circ Res 118 (2016), 1830–1843.
[5] Gilbert, R.E., Krum, H., Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 385 (2015), 2107–2117.
[6] Scheen, A.J., Paquot, N., Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 39 (2013), 179–190.
[7] Scirica, B.M., Braunwald, E., Raz, I., Cavender, M.A., Morrow, D.A., Jarolim, P., et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation, 132, 2015, e198.
[8] Standl, E., Erbach, M., Schnell, O., Dipeptidyl-peptidase-4 inhibitors and heart failure: class effect, substance-specific effect, or chance effect?. Curr Treat Options Cardiovasc Med, 16, 2014, 353.
[9] Kongwatcharapong, J., Dilokthornsakul, P., Nathisuwan, S., Phrommintikul, A., Chaiyakunapruk, N., Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials. Int J Cardiol 211 (2016), 88–95.
[10] Kundu, A., Sardar, P., Ghosh, S., Patel, P., Chatterjee, S., Meyer, T.E., Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Int J Cardiol 212 (2016), 203–205.
[11] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
[12] Fitchett, D., Zinman, B., Wanner, C., Lachin, J.M., Hantel, S., Salsali, A., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 37 (2016), 1526–1534.
[13] McMurray, J.J., Gerstein, H.C., Holman, R.R., Pfeffer, M.A., Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2 (2014), 843–851.
[14] Nauck, M., Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18 (2016), 203–216.
[15] Ussher, J.R., Drucker, D.J., Cardiovascular actions of incretin-based therapies. Circ Res 114 (2014), 1788–1803.
[16] White, W.B., Baker, W.L., Cardiovascular effects of incretin-based therapies. Annu Rev Med 67 (2016), 245–260.
[17] Waldrop, G., Zhong, J., Peters, M., Rajagopalan, S., incretin-based therapy for diabetes: what a cardiologist needs to know. J Am Coll Cardiol 67 (2016), 1488–1496.
[18] Mannucci, E., Monami, M., Cardiovascular safety of incretin-based therapies in type 2 diabetes: systematic review of integrated analyses and randomized controlled trials. Adv Ther 34 (2017), 1–40.
[19] Ravassa, S., Zudaire, A., Diez, J., Glucagon-like peptide 1 and cardiac cell survival. Endocrinol Nutr 59 (2012), 561–569.
[20] Zhao, T.C., Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection. Cardiovasc Diabetol, 12, 2013, 90.
[21] Verges, B., Bonnard, C., Renard, E., Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab 37 (2011), 477–488.
[22] Kang, Y.M., Jung, C.H., Cardiovascular effects of glucagon-like peptide-1 receptor agonists. Endocrinol Metab (Seoul) 31 (2016), 258–274.
[23] Khan, M.A., Deaton, C., Rutter, M.K., Neyses, L., Mamas, M.A., Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev 18 (2013), 141–148.
[24] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
[25] Thrainsdottir, I., Malmberg, K., Olsson, A., Gutniak, M., Ryden, L., Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 1 (2004), 40–43.
[26] Nikolaidis, L.A., Mankad, S., Sokos, G.G., Miske, G., Shah, A., Elahi, D., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004), 962–965.
[27] Sokos, G.G., Nikolaidis, L.A., Mankad, S., Elahi, D., Shannon, R.P., Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12 (2006), 694–699.
[28] Sokos, G.G., Bolukoglu, H., German, J., Hentosz, T., Magovern, G.J. Jr., Maher, T.D., et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 100 (2007), 824–829.
[29] Halbirk, M., Norrelund, H., Moller, N., Holst, J.J., Schmitz, O., Nielsen, R., et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 298 (2010), H1096–H1102.
[30] Nathanson, D., Ullman, B., Lofstrom, U., Hedman, A., Frick, M., Sjoholm, A., et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 55 (2012), 926–935.
[31] Munaf, M., Pellicori, P., Allgar, V., Wong, K., A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure. Int J Pept, 2012, 2012, 249827.
[32] Lepore, J.J., Olson, E., Demopoulos, L., Haws, T., Fang, Z., Barbour, A.M., et al. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart failure 4 (2016), 559–566.
[33] Li, L., Li, S., Liu, J., Deng, K., Busse, J.W., Vandvik, P.O., et al. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC Cardiovasc Disord, 16, 2016, 91.
[34] Wang, T., Wang, F., Zhou, J., Tang, H., Giovenale, S., Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials. Diabetes Metab Res Rev 32 (2016), 843–857.
[35] Fisher, M., Petrie, M.C., Ambery, P.D., Donaldson, J., Ye, J., Mc Murray, J.J., Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol 3 (2015), 697–703.
[36] Ferdinand, K.C., Botros, F.T., Atisso, C.M., Sager, P.T., Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol, 15, 2016, 38.
[37] Scheen, A.J., Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonists. Lancet Diabetes Endocrinol 3 (2015), 667–669.
[38] Velez, M., Peterson, E.L., Wells, K., Swadia, T., Sabbah, H.N., Williams, L.K., et al. Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes. J Card Fail 21 (2015), 2–8.
[39] Filion, K.B., Azoulay, L., Platt, R.W., Dahl, M., Dormuth, C.R., Clemens, K.K., et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 374 (2016), 1145–1154.
[40] Chen, W.R., Hu, S.Y., Chen, Y.D., Zhang, Y., Qian, G., Wang, J., et al. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 170 (2015), 845–854.
[41] Chen, W.R., Shen, X.Q., Zhang, Y., Chen, Y.D., Hu, S.Y., Qian, G., et al. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine 52 (2016), 516–526.
[42] Kumarathurai, P., Anholm, C., Nielsen, O.W., Kristiansen, O.P., Molvig, J., Madsbad, S., et al. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study. Cardiovasc Diabetol, 15, 2016, 105.
[43] Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, et al. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine 2016; Nov 9 [Epub ahead of print].
[44] Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R.S., Nielsen, R., Hanselmann, A., et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19 (2017), 69–77.
[45] Margulies, K.B., Hernandez, A.F., Redfield, M.M., Givertz, M.M., Oliveira, G.H., Cole, R., et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316 (2016), 500–508.
[46] Htike, Z.Z., Yates, T., Brady, E.M., Webb, D., Gray, L.J., Swarbrick, D., et al. Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). Cardiovasc Diabetol, 15, 2016, 102.
[47] Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
[48] Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
[49] Zannad, F., Cannon, C.P., Cushman, W.C., Bakris, G.L., Menon, V., Perez, A.T., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
[50] Scirica, B.M., Braunwald, E., Raz, I., Cavender, M.A., Morrow, D.A., Jarolim, P., et al. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130 (2014), 1579–1588.
[51] Scheen, A.J., Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes Metab 42 (2016), 71–76.
[52] Scheen, A.J., Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res Clin Pract 121 (2016), 204–214.
[53] Scheen, A.J., Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics. Diabetes Metab 42 (2016), 224–233.